In studies comparing IGF-1 and IGF-1 DES, it was observed that IGF-1 DES has stronger anabolic and hypoglycemic effects due to its lower binding affinity for IGFBPs. This lower affinity results in higher tissue uptake, though it may alter neuroprotective efficacy. In animal studies, standard doses of IGF-1 DES did not show significant neuroprotection in hypoxic-ischemic injury models, suggesting that optimal doses may differ from IGF-1. These findings highlight the importance of fine-tuning IGF-1 DES dosage to harness its full potential in therapeutic applications.
Frontiers in CNS Drug Discovery (2011) Frontiers in CNS Drug Discovery. Bentham Science Publishers.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about IGF-1 DES by Sixpex, consult with your doctor or healthcare professional.
Frontiers in CNS Drug Discovery (2011) Frontiers in CNS Drug Discovery. Bentham Science Publishers.
Frontiers in CNS Drug Discovery (2011) Frontiers in CNS Drug Discovery. Bentham Science Publishers.
Frontiers in CNS Drug Discovery (2011) Frontiers in CNS Drug Discovery. Bentham Science Publishers.
Home
